Immune checkpoint inhibitors (ICIs) offer potential life-saving benefits to patients with cancer but can cause multisystem immune-related adverse events (irAEs) that, when severe, may lead to significant morbidity and mortality.1,2 Data regarding the safety and efficacy of ICIs in patients with cancer receiving maintenance dialysis are extremely limited because these patients were excluded from all pivotal clinical trials of ICIs. Addressing this knowledge gap is particularly important because cancer rates are higher in patients receiving dialysis than in the US general population.